1. Department of Oncology, Affiliated Dongyang People's Hospital of Wenzhou Medical University, Dongyang, Zhejiang 322100,China
2. Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China
3. Department of Pharmaceutical Sciences, University of North Texas Health Science Center, Fort Worth, Texas 76107, USA
Cancer is a leading cause of death and poor quality of life globally. Even though several strategies are devised to reduce deaths, reduce chronic pain and improve the quality of life, there remains a shortfall in the adequacies of these cancer therapies. Among the cardinal steps towards ensuring optimal cancer treatment are early detection of cancer cells and drug application with high specificity to reduce toxicities. Due to increased systemic toxicities and refractoriness with conventional cancer diagnostic and therapeutic tools, other strategies including nanotechnology are being employed to improve diagnosis and mitigate disease severity. Over the years, immunotherapeutic agents based on nanotechnology have been used for several cancer types to reduce the invasiveness of cancerous cells while sparing healthy cells at the target site. Nanomaterials including carbon nanotubes, polymeric micelles and liposomes have been used in cancer drug design where they have shown considerable pharmacokinetic and pharmacodynamic benefits in cancer diagnosis and treatment. In this review, we outline the commonly used nanomaterials which are employed in cancer diagnosis and therapy. We have highlighted the suitability of these nanomaterials for cancer management based on their physicochemical and biological properties. We further reviewed the challenges that are associated with the various nanomaterials which limit their uses and hamper their translatability into the clinical setting in certain cancer types.
Keywords: nanomaterials, nanotechnology, cancer, diagnosis, treatment
Cancer is a leading cause of death and a global health burden. It was estimated that there would be 18.1 million new cancer cases and 9.6 million cancer-related deaths by 2018. Cancer is a disease characterized by uncontrolled cell proliferation that spreads from an initial focal point to other parts of the body to cause death. For these reasons, it is key to ensure earlier detection and treatment of cancers to reduce disease spread and mortalities. Amongst the widely used strategies, today in cancer research is nanotechnology. Nanotechnology has led to several promising results with its applications in the diagnosis and treatment of cancer, including drug delivery, gene therapy, detection and diagnosis, drug carriage, biomarker mapping, targeted therapy, and molecular imaging. Nanotechnology has been applied in the development of nanomaterials, such as gold nanoparticles and quantum dots, which are used for cancer diagnosis at the molecular level. Molecular diagnostics based on nanotechnology, such as the development of biomarkers, can accurately and quickly detect the cancers. Nanotechnology treatments, such as the development of nanoscale drug delivery, can ensure precise cancerous tissue targeting with minimal side effects[5, 6]. Due to its biological nature, nanomaterials can easily cross cell barriers. Over the years, nanomaterials have been used in the treatment of tumors, due to their active and passive targeting. Although many drugs can be used to treat cancers, the sensitivity of the drugs generally leads to inadequate results and can have various side effects, as well as damage to the healthy cells. In view of that, several studies have examined different forms of nanomaterials, such as liposomes, polymers, molecules, and antibodies, with the conclusion that a combination of these nanomaterials in cancer drug design can achieve a balance between increasing efficacy and reducing the toxicity of drugs. However, due to the potential toxicity of nanomaterials, there is still a lot of advancement to be done on them before their readily acceptance in the clinic for cancer management. With the rapid development of nanotechnology, this paper will review its application in cancer diagnosis and treatment with focus on their benefits and limitations during use (Figure 1).
Application of nanomaterials in cancer diagnosis and therapy.
Genetic mutations can cause changes in the synthesis of certain biomolecules leading to uncontrolled cell proliferation and ultimately cancerous tissues. Cancers can be classified as either benign or malignant. Benign tumors are confined to the origin of cancer while malignant tumors actively shed cells that invade surrounding tissues as well as distant organs. Cancer diagnostic and therapeutic strategies are targeted at early detection and inhibition of cancerous cell growth and their spread. Notable among the early diagnostic tools for cancers is the use of positron emission tomography (PET), magnetic resonance imaging (MRI), computed tomography (CT) and ultrasound. These imaging systems, however, are limited by their inadequate provision of relevant clinical information about different cancer types and the stage. Hence it makes it difficult to obtain a full evaluation of the disease state based on which an optimum therapy can be provided [11, 12].
In the past few decades, the application of nanoparticles in cancer diagnosis and monitoring has attracted a lot of attention with several nanoparticle types being used today for molecular imaging. Due to their advantages including small size, good biocompatibility, and high atomic number, they have gained prominence in recent cancer research and diagnosis. Nanoparticles used in cancer such as semiconductors, quantum dots and iron oxide nanocrystals possess optical, magnetic or structural properties that are less common in other molecules . Different anti-tumor drugs and biomolecules including peptides, antibodies or other chemicals, can be used with nanoparticles to label highly specific tumors, which are useful for early detection and screening of cancer cells.
For cancer diagnostics, imaging of tumor tissue with nanoparticles has made it possible to detect cancer in its early stages. In lung cancer, the detection of metastases can be determined by developing immune superparamagnetic iron oxide nanoparticles (SPIONs) that can be used in MRI imaging with the cancer cell lines as the target for the SPIONs . Recent studies have shown a high specificity of SPIONs with no known side effects, making them suitable building blocks for aerosols in lung cancer MRI imaging[16-18,19].
Magnetic powder imaging has also been used in tomographic imaging technology where it has shown a high resolution and sensitivity to cancer tissues. In animal experiments, nebulization of the lungs has been achieved using magnetic nanoparticles (MNPs) with Epidermal growth factor receptor (EGFR), a commonly expressed protein in non-small cell lung cancer (NSCLC) cases as a target. Further, in vitro studies using nanosystem for positron emission tomography (PET) have also been developed based on self-assembled amphiphilic dendritic molecules. These dendritic molecules spontaneously assemble into uniform supramolecular nanoparticles with abundant PET reporting units on the surface. By taking advantage of dendritic multivalence and the enhanced penetration and retention (EPR) effect, the dendritic nanometer system effectively accumulates in tumors, resulting in extremely sensitive and specific imaging of various tumors while reducing treatment toxicities.
In current research, nanotechnology can validate cancer imaging at the tissue, cell, and molecular levels. This is achieved through the capacity of nanotechnology applications to explore the tumor's environment, For instance, pH- response to fluorescent nanoprobes can help detect fibroblast activated protein-a on the cell membrane of tumor-associated fibroblasts. Hereon, we will discuss some nanotechnology-based spatial and temporal techniques that can help accurately track living cells and monitor dynamic cellular events in tumors.
The lack of ability to penetrate objects limits the use of visible spectral imaging. Quantum dots that emit fluorescence in the near-infrared spectrum (i.e., 700-1000 nanometers) have been designed to overcome this problem, making them more suitable for imaging colorectal cancer, liver cancer, pancreatic cancer, and lymphoma[22-24]. A second near-infrared (NIR) window (NIR-ii, 900-1700 nm) with higher tissue penetration depth, higher spatial and temporal resolution has also been developed to aid cancer imaging. Also, the development of a silver-rich Ag2Te quantum dots (QDs) containing a sulfur source has been reported to allow visualization of better spatial resolution images over a wide infrared range.
Another commonly used nanotechnology application is the use of nanoshells. Nanoshells are dielectric cores between 10 and 300 nanometers in size, usually made of silicon and coated with a thin metal shell (usually gold)[26, 27]. These nanoshells work by converting plasma-mediated electrical energy into light energy and can be flexibly tuned optically through UV-infrared emission/absorption arrays. Nanoshells are desirable because their imaging is devoid of the heavy metal toxicity even though their uses are limited by their large sizes.
Gold nanoparticle (AuNPs) is a good contrast agent because of its small size, good biocompatibility, and high atomic number. Research shows that AuNPs work by both active and passive ways to target cells. The principle of passive targeting is governed by a gathering of the gold nanoparticles to enhance imaging because of the permeability tension effect (EPR) in tumor tissues. Active targeting, on the other hand, is mediated by the coupling of AuNPs with tumor-specific targeted drugs, such as EGFR monoclonal antibodies, to achieve AuNP active targeting of tumor cells (Figure 2). When the energy exceeds 80kev, the mass attenuation rate of gold becomes higher than alternative elements like iodine, indicating a greater prospect gold nanoparticles . Rand et al. mixed AuNPs with liver cancer cells and found that using X-ray imaging, the clusters of liver cancer cells in the gold nanocomposite group were significantly stronger than those in the liver cancer cells alone. These findings have important implications for early diagnosis, with the technique allowing tumors as small as a few millimeters in diameter to be detected in the body.
Cancer biomarkers are biological features whose expression indicates the presence or state of a tumor. Such markers are used to study cellular processes, to monitor or identify changes in cancer cells, and these results could ultimately lead to a better understanding of tumors. Biomarkers can be proteins, protein fragments or DNA. Among them, tumor biomarkers, which are indicators of a tumor, can be tested to verify the presence of specific tumors. Tumor biomarkers ideally should possess a high sensitivity (>75%) and specificity (99.6%). Under current medical conditions, biomarkers from blood, urine, or saliva samples are used to screen individuals for cancer risk. But these biomarkers have not proven adequate for cancer screening. Therefore, several researchers have resorted to the study of extract patterns of abnormally expressed proteins, peptide fragments, glycans and autoantibodies from serum, urine, ascites or tissue samples from cancer patients[33-35]. With the development of proteomics technology, protein biomarkers for many cancers have been discovered.
In general, protein profiling tests would remove the high molecular weight proteins such as albumin and immunoglobulins. However, the removal of these proteins also removes the low molecular weight protein biomarkers conjugated to them, resulting in the loss of the biomarkers of interest. These low molecular weight proteins represent a potential biomarker-rich population[36-38]. Two studies led by Geho and Luchini came up with the method of capturing and enriching low molecular weight proteins by nanoparticles to obtain biomarkers from biological liquids, thus improving the screening of biomarkers[39, 40]. Nanoparticles compete with the carrier proteins by their surface characteristics, such as electric charge, or functional biomolecules, which are currently possessed by mesoporous silica particles, hydrogel nanoparticles, and carbon nanotubes[39-46].
Another method to improve screening with nanocarrier is to improve the sensitivity of mass spectrometry. The unique optical and thermal properties of carbon nanotubes enhance the energy-transfer efficiency of the analyte, contributing to the absorption and ionization of the analyte, and eliminate the interference of inherent matrix ions[46-48]. A third approach is to use nanotechnology to make lab-on-chip microfluidics devices that can be used for immuno-screening or to study the properties of tumor cells. For example, a system showing great promise is lab-on-a-chip for high performance multiplexed protein detection using quantum dots made of cadmium selenide (CdSe) core with a zinc sulfide (ZnS) shell linked to antibodies to carcinoembryonic antigen, cancer antigen 125 and Her-2/Neu. Another example is that cells growing on the surface of different sized nanometres, which were discovered by these nanometres across can differentiate between tumor cells. Suffice it to say that there are still false-positive and false-negative results from screening of biomarkers by nanotechnology, and we need to improve sensitivity without compromising specificity.
Various types of gold nanoparticles (different sizes, morphologies, and ligands) accumulate in tumor tissues by the action of osmotic tension effect (termed Passive targeting) or localize to specific cancer cells in a ligand-receptor binding way (termed Active targeting).
The development of nanotechnology is based on the usage of small molecular structures and particles as tools for delivering drugs. Nano-carriers such as liposomes, micelles, dendritic macromolecules, quantum dots, and carbon nanotubes have been widely used in cancer treatment.
Liposomes are one of the most studied nanomaterials, which are nanoscale spheres composed of natural or synthesized phospholipid bilayer membrane and water phase nuclei. Because of the amphiphilicity of phospholipids, liposomes form spontaneously, allowing hydrophilic drugs to preferentially stay in the monolayer liposome while hydrophobic ones form before the multilayer liposome. Some drugs could be incorporated into liposomes by exchanging them from acidic buffer to the neutral buffer. Neutral drugs can be transported in liposomes also, but due to a poor avidity for acidic environments, they are not readily released from the inside of the liposomes. Other mechanisms of drug delivery are the combination of saturated drugs with organic solvents to form liposomes. Under the influence of the EPR effect, the vesicle of size around 4000 kDa or 500 nm can be allowed into the tumor by the gaps in vessels. In tumors they can fuse with cells, are internalized by endocytosis, and release drugs in the intracellular space. In the case of the appropriate pH, redox potential, ultrasonic and under the electromagnetic field, the liposome can also release the drug through passive or active ligand-mediated activity. The targeted therapy has an advantage in the vascular system, micrometastases, and blood cancers. It has been shown that the half-life of liposome is affected by size. The liposome up to 100 nanometers easily penetrate the tumor and stay longer, while the half-life of the bigger liposome is shorter because they are easily recognized and cleared by the mononuclear phagocyte system. Liposome-bound antibodies target tumor-specific antigens to ensure active targeting and then transport drugs to the tumor. With a lot of pharmacokinetic benefits, some liposomal drugs are approved for clinical therapy (Table 1). For instance, liposomal forms of adriamycin have been used for the management of metastatic ovarian cancer where they have shown appreciable clinical benefit[56, 57].
Based on the structure and the diameter, Carbon nanotubes (CNTs) can be categorized into two kinds, the single-walled CNTs (SWNTs) and the multiwalled CNTs (MWNTs). The SWNTs are composed of monolithic cylindrical graphene, and the MWNTs are composed of concentric graphene. Because of the physical and chemical properties of carbon nanotubes, that include surface area, mechanical strength, metal properties, electrical and thermal conductivity, it is a candidate well suited for large-scale biomedical applications. Carbon nanotubes also possess a property that allows them to absorb light from the near-infrared (NIR) region, causing the nanotubes to heat up by the thermal effect, hence can target tumor cells[60-62]. The natural forms of carbon nanotubes promote noninvasive penetration of biofilms and are regarded as highly competent carriers for the transport of various drug molecules into living cells. Due to the suitability of carbon nanotubes, drugs such as paclitaxel are assembled with them and administered both in vitro and in vivo for cancer treatment.
Polymeric nanoparticles (PNPs) are the inventions that relate to a solid micelle with a particle size range of 10-1000 nm. PNPs are collectively known as polymer nanoparticle, nanospheres, nanocapsules or polymer micelles and they were the first polymers reported for drug delivery systems. PNPs serve as drug carriers for hydrophobic drugs and are widely used for drug discovery[66-68]. The PNPs constructed from amphiphilic polymers with a hydrophilic and hydrophobic block can perform rapid self-assembly because of the hydrophobic interactions in an aqueous solution. The PNPs can capture the hydrophobic drugs because of a covalent bond or the interaction via a hydrophobic core. Thus, to carry the hydrophilic charged molecules, such as proteins, peptides, and nucleic acids, these blocks are switched to allow interactions in the core and neutralize the charge.
Nanomaterial-carrying drugs in clinical trials of cancer treatment in the past five years.
|Liposome||2015||Doxorubicin||Platinum-Sensitive Ovarian Cancer||favorable risk-benefit profile|||
|Paclitaxel||Non-Small Cell Lung Cancer||considerable disease response and resection rate, with acceptable toxicity|||
|Ursolic acid||Advanced Solid Tumors||tolerable, manageable toxicity, improving patient remission rates|||
|Mitomycin C||advanced cancer||long circulation time, tolerable, effective|||
|2016||miR-34a Mimic||Advanced Solid Tumors||effective|||
|Vincristine Sulfate||Refractory Solid Tumors or Leukemias||without dose-limiting neurotoxicity|||
|5-fluorouracil and Leucovorin||Advanced Solid Tumors||lower peak plasma concentration, longer half-life, and increased area|||
|Cytarabine||Childhood Acute Lymphoblastic Leukemia||no permanent adverse neurological sequelae|||
|2017||Amphotericin||Acute Lymphoblastic Leukaemia||effective|||
|Irinotecan||Recurrent High-Grade Glioma||no unexpected toxicities|||
|2018||Cytarabine and Daunorubicin||Newly Diagnosed Secondary Acute Myeloid Leukemia||significantly longer survival rate|||
|Curcumin||Locally Advanced or Metastatic Cancer||durable|||
|Daunorubicin||Pediatric Relapsed/Refractory Acute Myeloid Leukemia||well-tolerated and showed high response rates|||
|Lipovaxin-MM||Malignant Melanoma||well-tolerated and without clinically significant toxicity|||
|Vincristine Sulfate||Acute Lymphoblastic Leukemia||provided a meaningful clinical benefit and safety|||
|Oligodeoxynucleotide||Refractory or Relapsed Haematological Malignancies||well-tolerated, effective|||
|2019||Eribulin||Solid Tumours||well-tolerated with a favorable pharmacokinetic profile|||
|Polymeric Micelles||2017||Epirubicin||Solid tumors||Well tolerated in patients with various solid tumors and exhibited less toxicity than conventional epirubicin formulations|||
|2018||Genexol-PM plus carboplatin||Ovarian Cancer||Non-inferior efficacy and well-tolerated toxicities|||
|2019||Paclitaxel (PTX)||Breast cancer||NK105 had a better PSN toxicity profile than PTX|||
The advantages of the higher thermodynamic stability and the smaller volume make the PNPs a suitable drug carrier with good endothelial cell permeability while avoiding kidney rejection[70-73]. The hydrophobic macromolecules and drugs can be transferred to the center of the PNPs, hence, the injection of PNPs suspension after being separated in an aqueous solution could achieve therapeutic effect. Importantly, by oral or parenteral administration, drugs can reach the target cells in different ways, potentially provide alternative ways to lower cytotoxicity in healthy tissues compared to the cancer cells. However, the major challenges in the use of PNPs for cancer nanomedicine still exist in how to effectively deliver the drugs to the target site with limited side effects or drug resistance. Recently, the PNPs have been used widely in the nanotechnology-based cancer drug design due to their excellent potential benefits for patient care. For example, adriamycin conjugated nanomaterial was used to treat several types of cancers where it achieved therapeutic effects to a decent degree. However, it also presented with many side-effects, such as toxicity and heart problems, thereby limiting its use. Such problems are overcome by Doxil (a liposomal form of doxorubicin), which is less associated with cardiotoxicity in patients, and hence may provide a safer nanomaterial synthetic approach for researchers in the future[74-77].
The dendrimers are nanocarriers that have a spherical polymer core with regularly spaced branches. As the dendritic macromolecule diameter increases, the tendency to tilt towards a spherical structure increases. There are usually two ways to synthesize dendrimers, a divergent method in which the dendrimers can grow outward from the central nucleus, and a convergence method, where the dendrimers grow inward from the edges and end up in the central nucleus[80, 81]. Various molecules including polyacrylamide, polyglycerol-succinic acid, polylysine, polyglycerin, poly2, 2bis (hydroxymethyl) propionic acid, and melamine are commonly used to form dendrimers. These dendritic macromolecules exhibit different chemical structures and properties, such as alkalinity, hydrogen bond capacity and charge, which can be regulated by growing dendritic macromolecules or changing the groups on the surface of dendritic macromolecules. In general, the dendritic drug conjugates are formed by the covalent binding of antitumor drugs to dendritic peripheral groups. Thus, several drug molecules can attach to each dendritic molecule and the release of these therapeutic molecules is controlled in part by the nature of the attachment. The physicochemical and biological properties of the polymer including the size, charge, multi-ligand groups, lipid bilayer interactions, cytotoxicity, internalization, plasma retention time, biological distribution, and filtration of dendritic macromolecules, have made dendrimers potential nanoscale carriers. Several studies have further shown that cancer cells with a high expression of folate receptors could form foils from dendritic molecules bound to folate[84-86]. An added advantage of dendrimers is their ability to bind to DNA as seen with the DNA-polyamides clustering DNA-poly(amidoamine) (DNAPAMAM), making them highly effective at killing cancer cells that express the folate receptor.
Quantum dots (QDs) are small particles or nanocrystals of semiconductor materials between 2 and 10 nanometers in size. The ratio of the height of the surface to the volume of these particles gives the QDs the intermediate electron property which is between a mass semiconductor and a discrete atom. Over the years, various QDs based techniques such as modification of QD conjugates and QD immunostaining have been developed. With the improvement of multiplexing capability, QDs conjugation greatly exceeds the monochromatic experiment in both time and cost-effectiveness. Moreover, at low protein expression levels and in a low context, QD immunostaining is more accurate than traditional immunochemical methods. In cancer diagnosis, QD immunostaining is a potential tool for the detection of various tumor biomarkers, such as a cell protein or other components of a heterogeneous tumor sample. Quantum dots can gather in specific parts of the body and transfer the drugs to those parts. The ability of the QDs to concentrate in a single internal organ makes them a potential solution against untargeted drug delivery, and possibly avoid the side effects of chemotherapy. The latest advancement in surface modification of QDs, which combine with biomolecules, including peptides and antibodies, in vivo, can be used to target tumors and make possible their potential applications in cancer imaging and treatment. Some studies combine QDs with prostate-specific antigen to label cancer, while others use QDs to make biomarkers that speed up the process with such immune markers having a more stable light intensity than traditional fluorescent immunomarkers. High sensitivity probes based on quantum dots have been reported for multicolor fluorescence imaging of cancer cells in vivo and can also be used to detect ovarian cancer marker cancer antigen 125 (CA125) in different types of specimens (such as fixed cells, tissue sections, and xenograft) . Besides, the light stability of quantum dot signals is more concrete and brighter than that of traditional organic dyes. Chen et al. successfully detected BC using quantum-dot-based probes, confirming that unlike traditional immunohistochemistry, quantum dot immunohistochemistry (IHC) can detect the very low expressions of Human Epidermal Growth Factor Receptor 2 (HER2) as well as multichannel detection[95, 96].
Nanotechnology has shown a lot of promise in cancer therapy over the years. By their improved pharmacokinetic and pharmacodynamic properties, nanomaterials have contributed to improved cancer diagnosis and treatment. Nanotechnology allows targeted drug delivery in affected organs with minimal systemic toxicities due to their specificities. However, as with other therapeutic options, nanotechnology is not completely devoid of toxicities and comes with few challenges with its use including systemic and certain organ toxicities, hence, causing setbacks with their clinical applications. Given the limitations with nanotechnology, more advancements must be done to improve drug delivery, maximize their efficacy while keeping the disadvantages to the minimum. By improving the interactions between the physicochemical properties of the nanomaterials employed, safer and more efficacious derivatives for diagnosis and treatment can be made available for cancer management. In sum, we sought to highlight the key advantages of nanotechnology and the shortfalls in their use to meet clinical needs for cancer. Adding to that, the therapeutic benefits of nanotechnology and future advancements could make them a therapeutic potential to be applied in other disease conditions. These may include ischemic stroke and rheumatoid arthritis which would require targeted delivery of a suitable pharmacologic agent at the affected site.
AuNPs: Gold Nanoparticles
BC: Breast Cancer
CA125: Cancer Antigen 125
CdSe: cadmium selenide
CNTs: Carbon Nanotubes
CT: Computed Tomography
EGFR: Epidermal Growth Factor Receptor
HER2: Human Epidermal Growth Factor Receptor 2
MNPs: Magnetic Nanoparticles
MWNTs: Multiwalled Carbon Nanotubes
MRI: Magnetic Resonance Imaging
NIR: Near Infrared
NSCLC: Non-small Cell Lung Cancer
PET: Positron Emission Tomography
PNPs: Polymeric Nanoparticles
QDs: Quantum Dots
SPION: Superparamagnetic Iron Oxide Nanoparticles
SWNTs: Single-walled Carbon Nanotubes
ZnS: zinc sulfifide
CJ and JH wrote the first draft. CJ, KW, AG and JH revised and edited the final manuscript. JH supervised the manuscript and provided critical input. All authors gave feedback and agreed on the final version of the manuscript.
This work was supported by the Affiliated Dongyang People's Hospital of Wenzhou Medical University and the Neurobiology of Aging and Alzheimer's Disease Training Program for JH (T32 AG020494).
The authors have declared that no competing interest exists.
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424
2. Hu J, Huang W, Huang S, ZhuGe Q, Jin K, Zhao Y. Magnetically active Fe3O4 nanorods loaded with tissue plasminogen activator for enhanced thrombolysis. Nano Research. 2016;9:2652-61
3. Huang L, Hu J, Huang S, Wang B, Siaw-Debrah F, Nyanzu M. et al. Nanomaterial Applications for Neurological Diseases and Central Nervous System Injury. Prog Neurobiol. 2017
4. Tran S, Degiovanni PJ, Piel B, Rai PJC, Medicine T. Cancer nanomedicine: a review of recent success in drug delivery. 2017; 6: 44.
5. Huang D, Wu K, Zhang Y, Ni Z, Zhu X, Zhu C. et al. Recent Advances in Tissue plasminogen activator-based nanothrombolysis for ischemic stroke. 2019; 58: 159.
6. Hu J, Huang S, Zhu L, Huang W, Zhao Y, Jin K. et al. Tissue Plasminogen Activator-Porous Magnetic Microrods for Targeted Thrombolytic Therapy after Ischemic Stroke. ACS Appl Mater Interfaces. 2018;10:32988-97
7. Chaturvedi VK, Singh A, Singh VK, Singh MP. Cancer Nanotechnology: A New Revolution for Cancer Diagnosis and Therapy. Current drug metabolism. 2019;20:416-29
8. Ye F, Zhao Y, El-Sayed R, Muhammed M, Hassan MJNT. Advances in nanotechnology for cancer biomarkers. 2018; 18: 103-23.
9. Bharali DJ, Mousa SA. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Pharmacology & therapeutics. 2010;128:324-35
10. Kim D, Jeong YY, Jon SJAN. A Drug-Loaded Aptamer?Gold Nanoparticle Bioconjugate for Combined CT Imaging and Therapy of Prostate Cancer. 2010; 4: 3689-96.
11. Akhter S, Ahmad I, Ahmad MZ, Ramazani F, Singh A, Rahman Z. et al. Nanomedicines as cancer therapeutics: current status. Current cancer drug targets. 2013;13:362-78
12. Wang J, Sui M, Fan W. Nanoparticles for tumor targeted therapies and their pharmacokinetics. Current drug metabolism. 2010;11:129-41
13. Popescu RC, Fufă MO, Grumezescu AM. Metal-based nanosystems for diagnosis. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie. 2015;56:635-49
14. Singh R. Nanotechnology based therapeutic application in cancer diagnosis and therapy. 3 Biotech. 2019 9: 415
15. Wan X, Song Y, Song N, Li J, Yang L, Li Y. et al. The preliminary study of immune superparamagnetic iron oxide nanoparticles for the detection of lung cancer in magnetic resonance imaging. Carbohydrate research. 2016;419:33-40
16. Sherry AD, Woods M. Chemical exchange saturation transfer contrast agents for magnetic resonance imaging. Annual review of biomedical engineering. 2008;10:391-411
17. Kim HS, Oh SY, Joo HJ, Son KR, Song IC, Moon WK. The effects of clinically used MRI contrast agents on the biological properties of human mesenchymal stem cells. NMR in biomedicine. 2010;23:514-22
18. Jafari A, Salouti M, Shayesteh SF, Heidari Z, Rajabi AB, Boustani K. et al. Synthesis and characterization of Bombesin-superparamagnetic iron oxide nanoparticles as a targeted contrast agent for imaging of breast cancer using MRI. Nanotechnology. 2015;26:075101
19. Stocke NA, Meenach SA, Arnold SM, Mansour HM, Hilt JZ. Formulation and characterization of inhalable magnetic nanocomposite microparticles (MnMs) for targeted pulmonary delivery via spray drying. International journal of pharmaceutics. 2015;479:320-8
20. Garrigue P, Tang J, Ding L, Bouhlel A, Tintaru A, Laurini E. et al. Self-assembling supramolecular dendrimer nanosystem for PET imaging of tumors. Proceedings of the National Academy of Sciences of the United States of America. 2018;115:11454-9
21. Ji T, Zhao Y, Wang J, Zheng X, Tian Y, Zhao Y. et al. Tumor Fibroblast Specific Activation of a Hybrid Ferritin Nanocage-Based Optical Probe for Tumor Microenvironment Imaging. 2013; 9: 2427-31.
22. Parungo CP, Ohnishi S, De Grand AM, Laurence RG, Soltesz EG, Colson YL. et al. In vivo optical imaging of pleural space drainage to lymph nodes of prognostic significance. Annals of surgical oncology. 2004;11:1085-92
23. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nature biotechnology. 2004;22:969-76
24. Dubertret B, Skourides P, Norris DJ, Noireaux V, Brivanlou AH, Libchaber A. In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science (New York, NY). 2002;298:1759-62
25. Zhang Y, Yang H, An X, Wang Z, Yang X, Yu M. et al. Controlled Synthesis of Ag(2) Te@Ag(2) S Core-Shell Quantum Dots with Enhanced and Tunable Fluorescence in the Second Near-Infrared Window. Small (Weinheim an der Bergstrasse, Germany). 2020;16:e2001003
26. Hirsch LR, Stafford RJ, Bankson JA, Sershen SR, Rivera B, Price RE. et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:13549-54
27. Loo C, Lin A, Hirsch L, Lee MH, Barton J, Halas N. et al. Nanoshell-enabled photonics-based imaging and therapy of cancer. Technology in cancer research & treatment. 2004;3:33-40
28. Nunes T, Pons T, Hou X, Van Do K, Caron B, Rigal M. et al. Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer. Journal of experimental & clinical cancer research: CR. 2019;38:306
29. Fu N, Hu Y, Shi S, Ren S, Liu W, Su S. et al. Au nanoparticles on two-dimensional MoS(2) nanosheets as a photoanode for efficient photoelectrochemical miRNA detection. The Analyst. 2018;143:1705-12
30. Fu F, Li L, Luo Q, Li Q, Guo T, Yu M. et al. Selective and sensitive detection of lysozyme based on plasmon resonance light-scattering of hydrolyzed peptidoglycan stabilized-gold nanoparticles. The Analyst. 2018;143:1133-40
31. Shrivas K, Nirmalkar N, Thakur SS, Deb MK, Shinde SS, Shankar R. Sucrose capped gold nanoparticles as a plasmonic chemical sensor based on non-covalent interactions: Application for selective detection of vitamins B(1) and B(6) in brown and white rice food samples. Food chemistry. 2018;250:14-21
32. Das PM, Bast RC Jr. Early detection of ovarian cancer. Biomark Med. 2008;2:291-303
33. Kuk C, Kulasingam V, Gunawardana CG, Smith CR, Batruch I, Diamandis EP. Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Mol Cell Proteomics. 2009;8:661-9
34. Fredolini C, Meani F, Luchini A, Zhou W, Russo P, Ross M. et al. Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology. AAPS J. 2010;12:504-18
35. Di Michele M, Marcone S, Cicchillitti L, Della Corte A, Ferlini C, Scambia G. et al. Glycoproteomics of paclitaxel resistance in human epithelial ovarian cancer cell lines: towards the identification of putative biomarkers. J Proteomics. 2010;73:879-98
36. Geho DH, Liotta LA, Petricoin EF, Zhao W, Araujo RPJCOiCB. The amplified peptidome: the new treasure chest of candidate biomarkers. 2006; 10: 50-5.
37. Zhou M, Lucas DA, Chan KC, Issaq HJ, Petricoin EF 3rd, Liotta LA. et al. An investigation into the human serum "interactome". Electrophoresis. 2004;25:1289-98
38. Merrell K, Southwick K, Graves SW, Esplin MS, Thulin CDJJoBTJ. Analysis of Low-Abundance, Low-Molecular-Weight Serum Proteins Using Mass Spectrometry. 2005; 15: 238-48.
39. Geho DH, Jones CD, Petricoin EF, Liotta LA. Nanoparticles: potential biomarker harvesters. Current opinion in chemical biology. 2006;10:56-61
40. Luchini A, Fredolini C, Espina BH, Meani F, Reeder A, Rucker S. et al. Nanoparticle technology: addressing the fundamental roadblocks to protein biomarker discovery. Current molecular medicine. 2010;10:133-41
41. Terracciano R, Pasqua L, Casadonte F, Frascà S, Preianò M, Falcone D. et al. Derivatized mesoporous silica beads for MALDI-TOF MS profiling of human plasma and urine. Bioconjugate chemistry. 2009;20:913-23
42. Meani F, Pecorelli S, Liotta L, Petricoin EF. Clinical application of proteomics in ovarian cancer prevention and treatment. Molecular diagnosis & therapy. 2009;13:297-311
43. Longo C, Patanarut A, George T, Bishop B, Zhou W, Fredolini C. et al. Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers. PloS one. 2009;4:e4763
44. Gaspari M, Ming-Cheng Cheng M, Terracciano R, Liu X, Nijdam AJ, Vaccari L. et al. Nanoporous surfaces as harvesting agents for mass spectrometric analysis of peptides in human plasma. Journal of proteome research. 2006;5:1261-6
45. Terracciano R, Gaspari M, Testa F, Pasqua L, Tagliaferri P, Cheng MM. et al. Selective binding and enrichment for low-molecular weight biomarker molecules in human plasma after exposure to nanoporous silica particles. Proteomics. 2006;6:3243-50
46. Najam-ul-Haq M, Rainer M, Szabó Z, Vallant R, Huck CW, Bonn GK. Role of carbon nano-materials in the analysis of biological materials by laser desorption/ionization-mass spectrometry. Journal of biochemical and biophysical methods. 2007;70:319-28
47. Xu S, Li Y, Zou H, Qiu J, Guo Z, Guo B. Carbon nanotubes as assisted matrix for laser desorption/ionization time-of-flight mass spectrometry. Analytical chemistry. 2003;75:6191-5
48. Wang CH, Li J, Yao SJ, Guo YL, Xia XH. High-sensitivity matrix-assisted laser desorption/ionization Fourier transform mass spectrometry analyses of small carbohydrates and amino acids using oxidized carbon nanotubes prepared by chemical vapor deposition as matrix. Analytica chimica acta. 2007;604:158-64
49. Jokerst JV, Raamanathan A, Christodoulides N, Floriano PN, Pollard AA, Simmons GW. et al. Nano-bio-chips for high performance multiplexed protein detection: determinations of cancer biomarkers in serum and saliva using quantum dot bioconjugate labels. Biosensors & bioelectronics. 2009;24:3622-9
50. Hung YC, Pan HA, Tai SM, Huang GS. A nanodevice for rapid modulation of proliferation, apoptosis, invasive ability, and cytoskeletal reorganization in cultured cells. Lab on a chip. 2010;10:1189-98
51. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends in pharmacological sciences. 2009;30:592-9
52. Bozzuto G, Molinari A. Liposomes as nanomedical devices. International journal of nanomedicine. 2015;10:975-99
53. Fenske DB, Cullis PR. Liposomal nanomedicines. Expert opinion on drug delivery. 2008;5:25-44
54. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Advanced drug delivery reviews. 2013;65:36-48
55. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. International journal of nanomedicine. 2006;1:297-315
56. Berger JL, Smith A, Zorn KK, Sukumvanich P, Olawaiye AB, Kelley J. et al. Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era. OncoTargets and therapy. 2014;7:1409-13
57. Chou H, Lin H, Liu JM. A tale of the two PEGylated liposomal doxorubicins. OncoTargets and therapy. 2015;8:1719-20
58. Kesharwani P, Iyer AK. Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery. Drug discovery today. 2015;20:536-47
59. Bianco A, Kostarelos K, Prato M. Applications of carbon nanotubes in drug delivery. Current opinion in chemical biology. 2005;9:674-9
60. Brennan ME, Coleman JN, Drury A, Lahr B, Kobayashi T, Blau WJ. Nonlinear photoluminescence from van Hove singularities in multiwalled carbon nanotubes. Optics letters. 2003;28:266-8
61. Kam NW, O'Connell M, Wisdom JA, Dai H. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:11600-5
62. Burlaka A, Lukin S, Prylutska S, Remeniak O, Prylutskyy Y, Shuba M. et al. Hyperthermic effect of multi-walled carbon nanotubes stimulated with near infrared irradiation for anticancer therapy: in vitro studies. Experimental oncology. 2010;32:48-50
63. Yu X, Gao D, Gao L, Lai J, Zhang C, Zhao Y. et al. Inhibiting Metastasis and Preventing Tumor Relapse by Triggering Host Immunity with Tumor-Targeted Photodynamic Therapy Using Photosensitizer-Loaded Functional Nanographenes. ACS nano. 2017;11:10147-58
64. Karnati KR, Wang Y. Understanding the co-loading and releasing of doxorubicin and paclitaxel using chitosan functionalized single-walled carbon nanotubes by molecular dynamics simulations. Physical chemistry chemical physics: PCCP. 2018;20:9389-400
65. Couvreur P. Polyalkylcyanoacrylates as colloidal drug carriers. Critical reviews in therapeutic drug carrier systems. 1988;5:1-20
66. Duncan R. The dawning era of polymer therapeutics. Nature reviews Drug discovery. 2003;2:347-60
67. Miyata K, Christie RJ, Kataoka KJR, Polymers F. Polymeric micelles for nano-scale drug delivery. 2011; 71: 227-34.
68. Blanco E, Bey EA, Khemtong C, Yang SG, Setti-Guthi J, Chen H. et al. Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer research. 2010;70:3896-904
69. Tian C, Feng J, Cho HJ, Datta SS, Prud'homme RK. Adsorption and Denaturation of Structured Polymeric Nanoparticles at an Interface. Nano letters. 2018;18:4854-60
70. Nakanishi T, Fukushima S, Okamoto K, Suzuki M, Matsumura Y, Yokoyama M. et al. Development of the polymer micelle carrier system for doxorubicin. Journal of controlled release: official journal of the Controlled Release Society. 2001;74:295-302
71. Savic R, Luo L, Eisenberg A, Maysinger D. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science (New York, NY). 2003;300:615-8
72. Jones M, Leroux J. Polymeric micelles - a new generation of colloidal drug carriers. European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 1999;48:101-11
73. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends in biotechnology. 2007;25:563-70
74. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature reviews Drug discovery. 2008;7:771-82
75. Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B. et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Annals of oncology: official journal of the European Society for Medical Oncology. 1998;9:711-6
76. Ewer MS, Martin FJ, Henderson C, Shapiro CL, Benjamin RS, Gabizon AA. Cardiac safety of liposomal anthracyclines. Seminars in oncology. 2004;31:161-81
77. Sharma G, Anabousi S, Ehrhardt C, Ravi Kumar MN. Liposomes as targeted drug delivery systems in the treatment of breast cancer. Journal of drug targeting. 2006;14:301-10
78. Svenson S, Tomalia DA. Dendrimers in biomedical applications-reflections on the field. Advanced drug delivery reviews. 2005;57:2106-29
79. Svenson SN, Tomalia DAJADDR. Dendrimers in biomedical applications—reflections on the field. 2005; 57: 2106-29.
80. Tomalia DA, Baker H, Dewald J, Hall M, Kallos G, Martin S. et al. Dendritic macromolecules: synthesis of starburst dendrimers. 1986; 19: 2466-8.
81. Tomalia DAH, Baker H, Dewald JR, Hall MJ, Smith PBJPJ. A New Class of Polymers: Starburst-Dendritic Macromolecules. 1985; 17: 117-32.
82. Palmerston Mendes L, Pan J, Torchilin VP. Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy. Molecules (Basel, Switzerland). 2017 22
83. Sherje AP, Jadhav M, Dravyakar BR, Kadam D. Dendrimers: A versatile nanocarrier for drug delivery and targeting. International journal of pharmaceutics. 2018;548:707-20
84. Wiener EC, Konda S, Shadron A, Brechbiel M, Gansow O. Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor. Investigative radiology. 1997;32:748-54
85. Quintana A, Raczka E, Piehler L, Lee I, Myc A, Majoros I. et al. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharmaceutical research. 2002;19:1310-6
86. Kono K, Liu M, Fréchet JM. Design of dendritic macromolecules containing folate or methotrexate residues. Bioconjugate chemistry. 1999;10:1115-21
87. Roy R, Baek MG. Glycodendrimers: novel glycotope isosteres unmasking sugar coding. case study with T-antigen markers from breast cancer MUC1 glycoprotein. Journal of biotechnology. 2002;90:291-309
88. Ekimov AI, Onushchenko AAJJL. Quantum Size Effect in Three-Dimensional Microscopic Semiconductor Crystals. 1981; 34: 363.
89. Kastner Marc AJPT. Artificial Atoms. 1993; 46: 24.
90. Shiohara A, Hoshino A, Hanaki K, Suzuki K, Yamamoto K. On the cyto-toxicity caused by quantum dots. Microbiology and immunology. 2004;48:669-75
91. Xiang QM, Wang LW, Yuan JP, Chen JM, Yang F, Li Y. Quantum dot-based multispectral fluorescent imaging to quantitatively study co-expressions of Ki67 and HER2 in breast cancer. Experimental and molecular pathology. 2015;99:133-8
92. Ruan Y, Yu W, Cheng F, Zhang X, Rao T, Xia Y. et al. Comparison of quantum-dots- and fluorescein-isothiocyanate-based technology for detecting prostate-specific antigen expression in human prostate cancer. IET nanobiotechnology. 2011;5:47
93. Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nature materials. 2005;4:435-46
94. Wang HZ, Wang HY, Liang RQ, Ruan KC. Detection of tumor marker CA125 in ovarian carcinoma using quantum dots. Acta biochimica et biophysica Sinica. 2004;36:681-6
95. Sung SY, Su YL, Cheng W, Hu PF, Chiang CS, Chen WT. et al. Graphene Quantum Dots-Mediated Theranostic Penetrative Delivery of Drug and Photolytics in Deep Tumors by Targeted Biomimetic Nanosponges. Nano letters. 2019;19:69-81
96. Chen C, Peng J, Xia HS, Yang GF, Wu QS, Chen LD. et al. Quantum dots-based immunofluorescence technology for the quantitative determination of HER2 expression in breast cancer. Biomaterials. 2009;30:2912-8
97. Mahner S, Meier W, du Bois A, Brown C, Lorusso D, Dell'Anna T. et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. European journal of cancer (Oxford, England: 1990). 2015;51:352-8
98. Lu B, Sun L, Yan X, Ai Z, Xu J. Intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy: a new method of neoadjuvant chemotherapy for stage III unresectable non-small cell lung cancer. Medical oncology (Northwood, London, England). 2015;32:345
99. Qian Z, Wang X, Song Z, Zhang H, Zhou S, Zhao J. et al. A phase I trial to evaluate the multiple-dose safety and antitumor activity of ursolic acid liposomes in subjects with advanced solid tumors. BioMed research international. 2015;2015:809714
100. Golan T, Grenader T, Ohana P, Amitay Y, Shmeeda H, La-Beck NM. et al. Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients. Cancer medicine. 2015;4:1472-83
101. Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, Stoudemire J. et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Investigational new drugs. 2017;35:180-8
102. Shah NN, Merchant MS, Cole DE, Jayaprakash N, Bernstein D, Delbrook C. et al. Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias. Pediatric blood & cancer. 2016;63:997-1005
103. Chiang NJ, Chao TY, Hsieh RK, Wang CH, Wang YW, Yeh CG. et al. A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors. BMC cancer. 2016;16:907
104. Levinsen M, Harila-Saari A, Grell K, Jonsson OG, Taskinen M, Abrahamsson J. et al. Efficacy and Toxicity of Intrathecal Liposomal Cytarabine in First-line Therapy of Childhood Acute Lymphoblastic Leukemia. Journal of pediatric hematology/oncology. 2016;38:602-9
105. Cornely OA, Leguay T, Maertens J, Vehreschild M, Anagnostopoulos A, Castagnola C. et al. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. The Journal of antimicrobial chemotherapy. 2017;72:2359-67
106. Clarke JL, Molinaro AM, Cabrera JR, DeSilva AA, Rabbitt JE, Prey J. et al. A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma. Cancer chemotherapy and pharmacology. 2017;79:603-10
107. Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK. et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2018;36:2684-92
108. Greil R, Greil-Ressler S, Weiss L, Schönlieb C, Magnes T, Radl B. et al. A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc(™)) in patients with locally advanced or metastatic cancer. Cancer chemotherapy and pharmacology. 2018;82:695-706
109. van Eijkelenburg NKA, Rasche M, Ghazaly E, Dworzak MN, Klingebiel T, Rossig C. et al. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study. Haematologica. 2018;103:1484-92
110. Gargett T, Abbas MN, Rolan P, Price JD, Gosling KM, Ferrante A. et al. Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma. Cancer immunology, immunotherapy: CII. 2018;67:1461-72
111. Schiller GJ, Damon LE, Coutre SE, Hsu P, Bhat G, Douer D. High-Dose Vincristine Sulfate Liposome Injection, for Advanced, Relapsed, or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in an Adolescent and Young Adult Subgroup of a Phase 2 Clinical Trial. Journal of adolescent and young adult oncology. 2018;7:546-52
112. Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E. et al. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. The Lancet Haematology. 2018;5:e136-e46
113. Evans TRJ, Dean E, Molife LR, Lopez J, Ranson M, El-Khouly F. et al. Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours. British journal of cancer. 2019;120:379-86
114. Mukai H, Kogawa T, Matsubara N, Naito Y, Sasaki M, Hosono A. A first-in-human Phase 1 study of epirubicin-conjugated polymer micelles (K-912/NC-6300) in patients with advanced or recurrent solid tumors. Invest New Drugs. 2017;35:307-14
115. Lee SW, Kim YM, Cho CH, Kim YT, Kim SM, Hur SY. et al. An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021). Cancer Res Treat. 2018;50:195-203
116. Fujiwara Y, Mukai H, Saeki T, Ro J, Lin YC, Nagai SE. et al. A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. Br J Cancer. 2019;120:475-80
Corresponding author: Dr. Jiangnan Hu, M.D., Department of Pharmaceutical Sciences, University of North Texas Health Science Center, Fort Worth, Texas 76107, USA. E-mail: jiangnan.huedu